Stockreport

PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission [Yahoo! Finance]

PaxMedica, Inc.  (PXMD) 
PDF treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of sura [Read more]